Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study
Alimentary Pharmacology & Therapeutics2020Vol. 51(11), pp. 1039–1046
Citations Over TimeTop 10% of 2020 papers
Aurélien Amiot, Jérôme Filippi, Véred Abitbol, Guillaume Cadiot, David Laharie, Mélanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin‐Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stéphane Nancey, Jean‐Marc Gornet, Stéphane Nahon, Guillaume Bouguen, Stéphanie Viennot, Benjamin Pariente, Mathurin Fuméry, UC‐USK‐GETAID Study Group
Abstract
In a cohort of highly refractory patients with UC with multiple prior drug failures, ustekinumab provided steroid-free clinical remission in one-third of cases at weeks 12-16. Clinical severity and previous use of anti-TNF and vedolizumab therapies were associated with ustekinumab failure at weeks 12-16.
Related Papers
- → Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease(2018)129 cited
- → Double Biologic Therapy for Refractory Stricturing Crohn’s Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab(2020)21 cited
- → Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study(2022)11 cited
- → P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab(2021)
- → P688 Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn’s Disease After Failure of Anti-TNF Agents: Real-World Evidence(2024)